Targeting Pim kinases in hematological cancers: molecular and clinical review

M Bellon, C Nicot - Molecular Cancer, 2023 - Springer
Decades of research has recognized a solid role for Pim kinases in lymphoproliferative
disorders. Often up-regulated following JAK/STAT and tyrosine kinase receptor signaling …

Comprehensive insights that targeting PIM for cancer therapy: prospects and obstacles

L Chen, W Mao, C Ren, J Li… - Journal of Medicinal …, 2024 - ACS Publications
Proviral integration sitea for Moloney-murine leukemia virus (PIM) kinases are a family of
highly conserved serine/tyrosine kinases consisting of three members, PIM-1, PIM-2, and …

Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm

MFU Rahman, Y Yang, BT Le, A Dutta… - Nature …, 2022 - nature.com
Chronic inflammation is frequently associated with myeloproliferative neoplasms (MPN), but
the role of inflammation in the pathogenesis of MPN remains unclear. Expression of the …

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms

T Kong, LY Yu, ABA Laranjeira… - American journal of …, 2023 - Wiley Online Library
Small molecule inhibitors targeting JAK2 provide symptomatic benefits for myeloproliferative
neoplasm (MPN) patients and are among first‐line therapeutic agents. However, despite all …

Pim kinases: important regulators of cardiovascular disease

S Nock, E Karim, AJ Unsworth - International Journal of Molecular …, 2023 - mdpi.com
Pim Kinases; Pim-1, Pim-2, and Pim-3, are a family of constitutively active serine/threonine
kinases, widely associated with cell survival, proliferation, and migration. Historically …

Fibrosis and bone marrow: Understanding causation and pathobiology

K Ghosh, DK Shome, B Kulkarni, MK Ghosh… - Journal of Translational …, 2023 - Springer
Bone marrow fibrosis represents an important structural change in the marrow that interferes
with some of its normal functions. The aetiopathogenesis of fibrosis is not well established …

AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor

K Ingle, JF LaComb, LM Graves, AT Baines… - PLoS …, 2023 - journals.plos.org
Pancreatic cancer is one of the leading causes of cancer deaths, with pancreatic ductal
adenocarcinoma (PDAC) being the most common subtype. Advanced stage diagnosis of …

[HTML][HTML] Recent advances in therapies for primary myelofibrosis

W Vainchenker, N Yahmi, V Havelange, C Marty… - Faculty …, 2023 - ncbi.nlm.nih.gov
Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET)
form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven …

Ruxolitinib alleviates inflammation, apoptosis, and intestinal barrier leakage in ulcerative colitis via STAT3

C Li, Y Xu, T Gao, S Zhang, Z Lin, S Gu… - Inflammatory Bowel …, 2023 - academic.oup.com
Lay Summary We studied the effect and mechanism of ruxolitinib on ulcerative colitis. We
discovered that ruxolitinib administration significantly alleviated murine colitis by relieving …

New treatments for myelofibrosis

D Tremblay, R Mesa - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement Currently approved therapies for myelofibrosis (MF) consist of JAK
inhibitors, which produce meaningful improvements in spleen size and symptom burden but …